Wedelolactone suppresses cell proliferation and migration through AKT and AMPK signaling in melanoma

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Melanoma is a highly malignant cancer with poor treatment sensitivity and high mortality rates.
• There is an urgent need for novel therapeutic agents to combat melanoma.
• Wedelolactone (WDL), a natural compound, exhibits antiproliferative properties.
• Investigating WDL's effects and mechanisms in melanoma is crucial.

Purpose of the Study:

• To evaluate the anti-cancer effects of Wedelolactone (WDL) on melanoma.
• To elucidate the underlying molecular mechanisms of WDL action in melanoma cells.
• To assess the in vivo efficacy of WDL in a melanoma xenograft model.

Main Methods:

• Melanoma cell line MV3 cells were treated with WDL.
• Cell proliferation, invasion, and migration were monitored.
• Expression levels of apoptosis-related proteins (Bax, Bcl-2) and cell-cycle regulators (cyclin D, PCNA, p21) were analyzed.
• Activation of AKT and AMPK signaling pathways was assessed.
• In vivo anti-melanoma activity was evaluated using a xenograft nude mice model.

Main Results:

• WDL significantly inhibited MV3 cell proliferation, migration, and invasion.
• WDL treatment increased the expression of pro-apoptotic Bax and decreased anti-apoptotic Bcl-2.
• WDL suppressed cyclin D expression while upregulating p21 expression.
• WDL inhibited AKT pathway activation and induced AMPK pathway activation.
• The induction of p21 by WDL was dependent on the AMPK signaling pathway.
• WDL demonstrated significant melanoma inhibition in the in vivo xenograft model.

Conclusions:

• Wedelolactone suppresses melanoma cell proliferation, migration, and invasion.
• WDL modulates apoptosis and cell-cycle regulatory proteins in melanoma.
• WDL exerts its effects by regulating AKT and AMPK signaling pathways.
• WDL shows therapeutic potential for melanoma treatment.